AI investors

AI Therapeutics is a clinical-stage biopharmaceutical company that utilizes a proprietary artificial intelligence platform, Guardian Angel, to accelerate drug discovery and development. The company focuses on matching existing drugs or new chemical entities with specific disease indications through deep learning and high-throughput screening. Their pipeline primarily targets rare diseases, oncology, and neurodegenerative disorders, with lead candidates currently in Phase 2 clinical trials. By leveraging AI to predict drug-target-disease interactions, the company aims to significantly reduce the time and cost associated with traditional drug development cycles.